Company Overview

Tenaya Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering, developing, and delivering therapies for heart disease, with a primary emphasis on genetic and rare cardiomyopathies. The company operates within the biotechnology and cardiovascular therapeutics industries and develops multiple therapeutic modalities, including gene therapy, cell therapy, and precision medicine approaches. Its core objective is to address the underlying molecular causes of heart disease rather than only managing symptoms, positioning the company within the emerging field of disease-modifying cardiovascular therapeutics.

The company’s principal programs have focused on inherited forms of cardiomyopathy such as arrhythmogenic right ventricular cardiomyopathy (ARVC), hypertrophic cardiomyopathy (HCM), and heart failure-related conditions. Revenue generation has historically been limited because Tenaya remains primarily in the research and clinical development stage, with funding derived largely from public equity financing, collaborations, and investment capital rather than commercialized products. Founded in 2016, Tenaya Therapeutics evolved from advances in cardiovascular genetics and regenerative medicine research developed by scientific founders associated with major academic institutions and biotechnology research programs.

Business Operations

Tenaya Therapeutics organizes its operations around integrated cardiovascular therapeutic platforms that include Gene Therapy, Cell Therapy, and Precision Medicine programs. The company develops adeno-associated virus (AAV)-based gene therapies designed to restore or replace defective cardiac genes, induced pluripotent stem cell-derived cardiac therapies intended to regenerate damaged heart tissue, and small molecule or targeted precision therapies aimed at genetically defined cardiovascular diseases. Key pipeline programs have included TN-201 for MYBPC3-associated hypertrophic cardiomyopathy and TN-401 for PKP2-associated arrhythmogenic cardiomyopathy.

Operations are centered primarily in the United States, where the company conducts research, preclinical development, and clinical activities. Tenaya controls proprietary cardiovascular disease modeling platforms, genetic engineering capabilities, and translational research assets supporting therapeutic discovery and development. The company has maintained collaborations with academic institutions, contract research organizations, manufacturing partners, and biotechnology service providers to support clinical development and scalable production. Public filings and investor materials identify intellectual property surrounding cardiac-targeted delivery systems and engineered therapeutic constructs as part of its strategic asset base.

Strategic Position & Investments

Tenaya Therapeutics’ strategic direction has centered on becoming a diversified cardiovascular therapeutics company capable of addressing multiple forms of heart disease through modality-specific platforms. The company has invested significantly in advancing clinical-stage gene therapy candidates, expanding translational cardiovascular research capabilities, and strengthening manufacturing readiness for potential future commercialization. Its development strategy emphasizes genetically validated cardiovascular targets, where disease mechanisms are well characterized and patient populations can potentially be identified through genetic testing.

The company has also invested in platform technologies intended to improve cardiac specificity, durability of gene expression, and delivery efficiency. Tenaya’s broader positioning reflects growing industry interest in cardiovascular gene therapy, an area historically less developed than oncology or rare neurological disease therapeutics. While the company does not maintain a large portfolio of independently operating subsidiaries, it has established strategic scientific and operational collaborations supporting research, manufacturing, and clinical execution. Available public disclosures indicate continued prioritization of rare inherited cardiovascular diseases as an entry point for future expansion into broader heart failure and cardiac regenerative medicine applications.

Geographic Footprint

Tenaya Therapeutics is headquartered in South San Francisco, California, within the broader biotechnology ecosystem of the San Francisco Bay Area. Its principal operational footprint remains concentrated in the United States, where most research, development, regulatory, and corporate activities are conducted. Clinical development efforts involve relationships with medical centers and research institutions specializing in inherited cardiovascular disease and advanced cardiac care.

Although the company’s direct commercial presence outside the United States remains limited due to its clinical-stage status, Tenaya participates in a globally competitive biotechnology sector with relevance to patient populations in North America, Europe, and parts of Asia-Pacific where inherited cardiomyopathies are actively diagnosed and studied. International influence is primarily expressed through scientific collaboration, intellectual property protection, and participation in multinational clinical and regulatory frameworks relevant to advanced therapeutics.

Leadership & Governance

Tenaya Therapeutics was co-founded by biotechnology entrepreneurs and cardiovascular researchers seeking to advance precision therapies for heart disease using regenerative medicine and genetic engineering technologies. Leadership has emphasized translating cutting-edge cardiovascular science into clinically viable therapies targeting diseases with significant unmet medical need. Public company communications and investor materials consistently describe a strategy focused on scientific rigor, differentiated cardiovascular specialization, and long-term platform development.

Key executives and leadership figures have included:

• Faraz Ali – Chief Executive Officer
• Brigit Riley, M.D. – Chief Medical Officer
• Paula Ferrero – Chief Financial Officer
• Whit Tingley – Chief Business Officer
• Mark Chao, M.D., Ph.D. – Former Chief Executive Officer and co-founder
• Deepak Srivastava, M.D. – Co-founder and scientific leader associated with cardiovascular research initiatives

The company is governed by a board of directors composed of biotechnology executives, scientific experts, and investment professionals with backgrounds in drug development, cardiovascular medicine, and life sciences financing. Public disclosures in SEC filings and corporate governance materials indicate an emphasis on clinical execution, capital allocation discipline, and advancement of genetically targeted cardiovascular therapies.